Our Approach
Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.
Pipeline
The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.
Clinical Trials
We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.
News
ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
19 March 2020
ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the CompanyMr. Squarer, a global biopharmaceutical leader, brings extensive oncology commercialization expertise as Company prepares to submit BLA in Q3 2020 Lausanne, Switzerland, March 19, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors,
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
10 January 2020
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical AffairsFormer Celgene and Wyeth leader with 30 years of global biopharmaceutical experience joins company as it prepares for first Biologics License Application (BLA) submission Lausanne, Switzerland, January 10, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
9 January 2020
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaExceeded primary endpoint target with 45.5% overall response rate, including 20% complete response rate, in 145-patient trial On track for Biologics License Application (BLA) submission in 3Q 2020 Lausanne, Switzerland, January 9, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs)
